{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:20Z","timestamp":1792784600107,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013927","name":"National MPS Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013927","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Austrian MPS Society"},{"name":"International Morquio Organization"},{"name":"Carol Ann Foundation"},{"name":"Japanese MPS Family Society"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30GM114736"],"award-info":[{"award-number":["P30GM114736"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R01HD065767"],"award-info":[{"award-number":["1R01HD065767"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ymgme.2017.12.434","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T02:59:30Z","timestamp":1514257170000},"page":"59-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Gene therapy for Mucopolysaccharidoses"],"prefix":"10.1016","volume":"123","author":[{"given":"Kazuki","family":"Sawamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hsuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos J.","family":"Alm\u00e9ciga-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.12.434_bb0005","first-page":"3421","article-title":"The mucopolysaccharidoses","volume":"136","author":"Neufeld","year":"2001","journal-title":"The Metabolic and Molecular Bases of Inherited Disease"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymgme.2010.09.010","article-title":"Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI","volume":"102","author":"Turbeville","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0015","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0020","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.bbmt.2016.08.015","article-title":"Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis-a ten-year report from the China children transplant group","volume":"22","author":"Wang","year":"2016","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2015.09.011","article-title":"Hematopoietic stem cell transplantation for Morquio A syndrome","volume":"117","author":"Yabe","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymgmr.2017.05.010","article-title":"Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: a 7years follow-up","volume":"12","author":"Barth","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0035","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0040","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/DDDT.S68562","article-title":"Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome","volume":"9","author":"Tomatsu","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0045","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/21678707.2015.1086640","article-title":"Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations","volume":"3","author":"Tomatsu","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/21678707.2016.1214572","article-title":"Current therapies for Morquio A syndrome and their clinical outcomes","volume":"4","author":"Sawamoto","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ymgme.2016.11.007","article-title":"Mucopolysaccharidosis IVA and glycosaminoglycans","volume":"120","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2012.133","article-title":"Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.transproceed.2016.10.007","article-title":"Cost analysis of transplantation in Japan, performed with the use of the national database","volume":"49","author":"Kitazawa","year":"2017","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0100","first-page":"547","article-title":"An update on gene therapy in China","volume":"11","author":"Shi","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0105","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0312-328","article-title":"Limb-saving medicines sought to prevent amputations","volume":"18","author":"Willyard","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0110","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S0140-6736(12)61992-8","article-title":"Europe gives gene therapy the green light","volume":"380","author":"Gruber","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0115","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0120","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coviro.2016.08.006","article-title":"Crossing the blood-brain-barrier with viral vectors","volume":"21","author":"Fu","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/mp.53.4.173","article-title":"Retroviral vectors","volume":"53","author":"Kurian","year":"2000","journal-title":"Mol. Pathol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2222\/jsv.65.27","article-title":"Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials","volume":"65","author":"Doi","year":"2015","journal-title":"Uirusu"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0145","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BJ20120146","article-title":"Lentiviral vectors: basic to translational","volume":"443","author":"Sakuma","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1399-0004.2000.580101.x","article-title":"Improvements in adenoviral vector technology: overcoming barriers for gene therapy","volume":"58","author":"Parks","year":"2000","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1006\/mthe.2001.0500","article-title":"Absence of germline infection in male mice following intraventricular injection of adenovirus","volume":"4","author":"Peters","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0160","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1089\/hum.1998.9.16-2331","article-title":"Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain","volume":"9","author":"Ghodsi","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.gt.3301869","article-title":"Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII","volume":"10","author":"Kamata","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0170","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ymthe.2003.07.004","article-title":"Improvement of skeletal lesions in mice with mucopolysaccharidosis type VII by neonatal adenoviral gene transfer","volume":"8","author":"Kanaji","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0175","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","article-title":"Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors","volume":"8","author":"Donsante","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0180","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0185","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/mt.2012.197","article-title":"Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity","volume":"20","author":"Rosas","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0190","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/JVI.70.5.3227-3234.1996","article-title":"Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors","volume":"70","author":"Ferrari","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0195","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","article-title":"Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step transduction in vivo","volume":"10","author":"McCarty","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0200","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/mt.2008.171","article-title":"Self-complementary AAV vectors; advances and applications","volume":"16","author":"McCarty","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0205","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0210","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0215","doi-asserted-by":"crossref","first-page":"20610","DOI":"10.1074\/jbc.M101559200","article-title":"Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer","volume":"276","author":"Walters","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0220","doi-asserted-by":"crossref","first-page":"9093","DOI":"10.1128\/JVI.00895-06","article-title":"Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6","volume":"80","author":"Wu","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0225","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1128\/JVI.72.2.1438-1445.1998","article-title":"Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions","volume":"72","author":"Summerford","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0230","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1099\/0022-1317-81-8-2077","article-title":"Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors","volume":"81","author":"Handa","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0235","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1128\/JVI.75.15.6884-6893.2001","article-title":"Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity","volume":"75","author":"Kaludov","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0240","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1172\/JCI57367","article-title":"The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice","volume":"121","author":"Bell","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0245","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1074\/jbc.M110.210922","article-title":"Terminal N-linked galactose is the primary receptor for adeno-associated virus 9","volume":"286","author":"Shen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0250","doi-asserted-by":"crossref","first-page":"9831","DOI":"10.1128\/JVI.00878-06","article-title":"The 37\/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9","volume":"80","author":"Akache","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0255","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0260","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ana.20150","article-title":"Prevention of neuropathology in the mouse model of Hurler syndrome","volume":"56","author":"Desmaris","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0265","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/hum.2015.170","article-title":"A preclinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome","volume":"27","author":"Winner","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0270","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/hmg\/ddm223","article-title":"Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes","volume":"16","author":"Fraldi","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/mthe.2001.0514","article-title":"Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery","volume":"5","author":"Fu","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0280","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1523\/JNEUROSCI.3558-04.2004","article-title":"Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum","volume":"24","author":"Cressant","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0285","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/exnr.1999.7176","article-title":"Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice","volume":"160","author":"Skorupa","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0290","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/mthe.1999.0005","article-title":"Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors","volume":"1","author":"Bosch","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0295","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/mthe.2001.0274","article-title":"Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII","volume":"3","author":"Frisella","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0300","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/10430340050015707","article-title":"Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse","volume":"11","author":"Sferra","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0305","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","article-title":"A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease","volume":"27","author":"Cearley","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0310","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/mt.2009.15","article-title":"AAV9: a potential blood-brain barrier buster","volume":"17","author":"Manfredsson","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0315","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0320","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1089\/hum.2013.005","article-title":"Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates","volume":"24","author":"Samaranch","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0325","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/mt.2015.212","article-title":"A comprehensive map of CNS transduction by eight recombinant adeno-associated virus serotypes upon cerebrospinal fluid administration in pigs","volume":"24","author":"Sorrentino","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0330","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0335","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ymgme.2006.02.012","article-title":"Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide","volume":"88","author":"Nishioka","year":"2006","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0340","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymgme.2008.01.007","article-title":"Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice","volume":"94","author":"Monta\u00f1o","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0345","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/mt.2010.32","article-title":"Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome","volume":"18","author":"Tomatsu","year":"2010","journal-title":"Mol. Ther."},{"issue":"2012","key":"10.1016\/j.ymgme.2017.12.434_bb0350","first-page":"65","article-title":"Current and emerging treatments and surgical interventions for Morquio A syndrome: a review","author":"Tomatsu","year":"2012","journal-title":"Res. Rep. Endocr. Disord."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0355","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0360","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0365","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnana.2014.00042","article-title":"Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse","volume":"8","author":"Schuster","year":"2014","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0370","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/gt.2017.18","article-title":"Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders","volume":"24","author":"Bey","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0375","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/gt.2014.16","article-title":"Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats","volume":"21","author":"Bucher","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0380","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","article-title":"Immune responses to adenovirus and adeno-associated virus in humans","volume":"6","author":"Chirmule","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0385","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/hum.2006.17.440","article-title":"Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors","volume":"17","author":"Halbert","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0390","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0395","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0400","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/hum.2012.179","article-title":"Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8","volume":"24","author":"Ferla","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0405","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/hum.2014.109","article-title":"Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial","volume":"26","author":"Ferla","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0410","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/humc.2013.208","article-title":"Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates","volume":"25","author":"Murrey","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0415","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0420","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymgme.2016.06.006","article-title":"Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model","volume":"119","author":"Hinderer","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0425","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0430","article-title":"AAV gene therapy for MPS1-associated corneal blindness","volume":"22","author":"Vance","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0435","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0440","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1089\/hum.2016.101","article-title":"Delivery of an adeno-associated virus vector into cerebrospinal fluid attenuates central nervous system disease in mucopolysaccharidosis type II mice","volume":"27","author":"Hinderer","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0445","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2016.184","article-title":"Prevention of neurocognitive deficiency in mucopolysaccharidosis type II mice by central nervous system-directed, AAV9-mediated Iduronate sulfatase gene transfer","volume":"28","author":"Laoharawee","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0450","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/mt.2011.220","article-title":"Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice","volume":"20","author":"Ruzo","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0455","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/hum.2012.029","article-title":"Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer","volume":"23","author":"Ruzo","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0460","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/emmm.201202083","article-title":"A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA","volume":"5","author":"Sorrentino","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0465","doi-asserted-by":"crossref","first-page":"16036","DOI":"10.1038\/mtm.2016.36","article-title":"Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery","volume":"3","author":"Fu","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0470","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0475","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/humc.2015.132","article-title":"A GLP-compliant toxicology and biodistribution study: systemic delivery of an rAAV9 vector for the treatment of mucopolysaccharidosis IIIB","volume":"26","author":"Meadows","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0480","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ymthe.2016.12.025","article-title":"Near-complete correction of profound metabolomic impairments corresponding to functional benefit in MPS IIIB mice after IV rAAV9-hNAGLU gene delivery","volume":"25","author":"Fu","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0490","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0495","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0500","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.mt.6300325","article-title":"Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle","volume":"16","author":"Tessitore","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0505","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/mt.2010.257","article-title":"Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer","volume":"19","author":"Cotugno","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0510","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/mt.2012.100","article-title":"Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease","volume":"20","author":"Chen","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0515","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mt.2015.189","article-title":"Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII","volume":"24","author":"Gurda","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2017.12.434_bb0520","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0525","series-title":"13th International Congress of Inborn Errors of Metabolism, ZFN-mediated in vivo genome editing results in phenotypic correction in MPS I and MPS II mouse models","author":"Dekeler","year":"2017"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0530","author":"RegenxBio"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0540","author":"Esteve"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0545","author":"Abeona"},{"key":"10.1016\/j.ymgme.2017.12.434_bb0550","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J. Clin. Invest."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217306169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217306169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T18:26:29Z","timestamp":1603563989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217306169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1096719217306169"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.434","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for Mucopolysaccharidoses","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}